PositiveID Corporation (fka PSID)

[greaseyfingers]

That was Then ~ This is Now

Listen to 12-26-12 SmallCapVoice Interview with PositiveID Corporation (PSID) at, http://smallcapvoice.com/blog/12-26-12-smallcapvoice-interview-with-positiveid-corporation-psid/

Positive ID's, CEO, William Caragol should be more of an authority, concerning PSID, more so, than anyone else, including everyone's opinion that's on iHub..IMO
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
PositveID's CEO William Caragol clearly says, in his 12-26-12 audio interview, http://smallcapvoice.com/blog/12-26-12-smallcapvoice-interview-with-positiveid-corporation-psid/, that the Request For Proposal vendor, or vendors will be chosen by DHS, to begin their Final Request For Proposal, pilot program's first phase Performance Competition Testing that's going to be announced by the end of the 3rd quarter of 2013, which would be June 30th.

This Final Request For Proposal, pilot program's first phase Competition Testing testing is projected to last throughout the remainder of 2013.

The integration of the BioWatch Generation3 program system is estimated at 3.1 billion dollars, during it's rollout over the next 5 to 6 years.

But, before this can happen, the BioWatch Generation3, Request For Propoal, chosen vendor, or vendors will have to complete the 18 months of Performance, first phase, Competion Testing.

Then, one and only one, of the competing vendors will be chosen for receiving the Final Request For Proposal Contract for the Operational, second phase Testing of the BioWatch Generation3 program.

After the Final Request For Proposal Contract for the Operational, second phase Testing of the BioWatch Generation3 program is completed in 2016.

DHS then may, upon it's discretion, implement and deploy up to 2500 BioWatch Generation Gen3 systems over the next 5 to 6 years.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The Final Request For Proposal for BioWatcj Generation 3 Performance Testing, during Stage 1, is expected to be released in the government's third quarter of fiscal 2013, which ends June 30th.

The Stage 1 contract is expected to have a performance testing period of 18 months.

The full roll-out of BioWatch Generation 3 is estimated at $3.1 billion over the next five years.
http://investors.positiveidcorp.com/releasedetail.cfm?releaseid=738584
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Performance-testing for the current-BioWatch-Gen-3 solicitation is 18 months, during the first stage of the competition.

The procurement for BioWatch Gen-3 Phase II will occur in two stages, DHS said.

The first stage involves performance testing of proposed biodetector systems competing against each other.

The period of performance testing for the current BioWatch Gen-3 solicitation is only 18 months, during the first stage of the competition.

The second phase, of the competition, involves operational testing and evaluation as well as production, deployment, sustainment and disposal.

DHS will only be making final one award for the second-stage of the BioWatch Gen-3 Competitive Down Selection.

Hopefully, PSID will be chosen as the one, and only winner during this Final Request For Proposal Phase of The Competition..

DHS asked interested companies to submit questions on the draft RFP by Feb. 11

Consulting firm Deltek, Herndon, Va., listed BioWatch Gen-3 as the only DHS program in its top 20 federal opportunities for contractors in fiscal year 2013. BioWatch Gen-3 represents a potential $3.1 billion value over five years, according to Deltek's estimates.

The DHS Office of Health Affairs runs the BioWatch program in partnership with the Environmental Protection Agency, the FBI and the Centers for Disease Control and Prevention.
http://www.hstoday.us/focused-topics/information-technology/single-article-page/more-info-on-biowatch-3-revealed-in-draft-solicitation.html

bull_investor Sunday, February 24, 2013 12:06:53 PM
Re: colocowboy post# 5794 Post #5796 of 5917

From the Governtment Accountability Office documents.

Estimated Schedule for Key Remaining Gen-3 Deployment Steps (as of September 2012):

ADE 2B:

Q4 2013 -to- Q2 2015 -- Laboratory Performance testing

Q4 2015 -to- Q3 2016 -- Operational testing, including IT network.

ADE 3:

Q4 2016 -to- Q1 2022 -- Production of approx. 2500 Gen-3 units and phased deployment to 50 jurisdictions

Q3 2022 -- Full operational capability.

** ADE - Acquisition Decision Event
** Q - Fiscal year quarter
Source: GAO Analysis of BioWatch program documents.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84947393

bull_investor Monday, February 18, 2013 8:30:39 AM
Re: None Post #5347 of 5917

Lets Break Down the Basics (BDB)-

==> Two key terms:

1 - RFP : solicitation through bidding process, here the solicitor knows what he wants, in this RFP, everything is listed, including price, risk factors, what is achievable and what is not. This is step 1 of procurement, a sure deal. according to news release this date could be on or before June 30 2013

2 - DRAFT RFP : is not a formal solicitation tool, rather it is used to gather comments and suggestions from potential offerors. The DRFP is mandatory for all competitive acquisitions expected to exceed $25 million; it is optional for all other acquisitions. It is designed to reduce proposal preparation and evaluation time and promote a clearer understanding to industry of the requirements with a goal of a more effective and less costly contract.

Now note those "two key terms" in the Feb 6, 2013 news release:

http://investors.positiveidcorp.com/releasedetail.cfm?releaseid=738584

Title: PositiveID Reports Issuance of Draft RFP From Dept of Homeland Security for BioWatch Generation 3

PositiveID Corporation ("PositiveID" or "Company") (OTCBB:PSID), a developer of biological detection and diagnostics solutions, today announced that the U.S. Department of Homeland Security ("DHS") released a draft request for proposal ("RFP") for Stage 1 of BioWatch Generation 3, an autonomous biodetection system designed to protect the nation against biological threats. The final RFP for Stage 1 is expected to be released in the government's third quarter of fiscal 2013, which ends June 30th. The Stage 1 contract is expected to have a performance period of 18 months. The full roll-out of BioWatch Generation 3 is estimated at $3.1 billion over the next five years.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84707176

bull_investor Sunday, February 24, 2013 11:25:42 AM
Re: Robsct post# 5787 Post #5792 of 5917

DHS PDF says:

"The Government anticipates awarding multiple contracts for Stage 1.
However, only one contract will be awarded under Stage 2
after a competive down selection between stages"

It says one contract for Stage 2 - what does one contract mean??
is it one vendor? or
can a contract be of multiple vendors(PSID & NOC)?

if it is one vendor, then most likely it is PSID,
since CEO was saying that in past press releases!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84946722
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Waiting in-anticipation for PSID to win the BioWatch-Gen3-Contract

August 6, 2012 (Investorideas.com newswire, www.biodefensestocks.com) Investorideas.com, a leader in research for independent investors issues a news alert for biodefense stocks.

PositiveID Corporation (OTCBB: PSID) and Northrop Grumman Corporation (NYSE:NOC) as both companies prepare for technology acquisitions and procurement for BioWatch Generation 3 this fall.

In July 2012, Northrop Grumman Corporation (NYSE:NOC) reported that its Next Generation Automated Detection System (NG-ADS) for homeland defense applications has successfully completed a rigorous field test and is ready for the program's next phase.

The NG-ADS technology is a competitor for the Department of Homeland Security's (DHS) upcoming BioWatch Gen-3 Phase II acquisition.

The program seeks to deploy a nationwide network of fully autonomous bio-detectors in major metropolitan areas across the United States to provide early warning of a biological attack. DHS recently announced that a request for proposals will be issued later this year.

The request for proposal got postponed by DHS, as we all know, into 2013.

As a fully automated biological detection system, the NG-ADS continuously collects air samples, analyzes the samples for the presence of multiple biological pathogens, and automatically reports results to public health officials multiple times each day through a secure data network.

More than 20,000 samples were collected and analyzed during the recent field test in a variety of indoor and outdoor locations in a major city in the United States .

"There are concerns that our nation won't be ready to respond should a biological attack occur," said Dave Tilles, director of Homeland Security programs at Northrop Grumman's Electronic Systems sector.

"Early warning provided by an automated detection system such as the NG-ADS will allow the nation's public health and public safety officials to proactively manage the response to a biological event to reduce exposure and treat the affected population to minimize casualties."

Since the successful field test, additional improvements have been made to the NG-ADS to enhance the system's performance while reducing its life-cycle cost.

The proven, life-saving capability of the NG-ADS draws upon Northrop Grumman's decade long experience developing, testing, deploying, and operating bio-detection systems for the U.S. government and other customers.

PositiveID Corporation (OTCBB: PSID) recently reported it added Dr. Kimothy Smith as Chief Technology Advisor to the Company and its Microfluidic Systems ("MFS") subsidiary. The Company will utilize Dr. Smith's expertise in the areas of biosurveillance, biodefense, biosecurity, molecular genetics and diagnostics, as it prepares for the release of the final request for proposal from the Department of Homeland Security ("DHS") for BioWatch Generation 3, a $3.1 billion procurement for an early warning system designed to detect the intentional release of airborne biological agents. The Company believes its M-BAND system is one of the only technologies capable of addressing the requirements of BioWatch Generation 3.

About PositiveID Corporation

PositiveID Corporation is an emerging growth company and developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America 's homeland defense. Its wholly-owned subsidiary, Microfluidic Systems, or MFS, is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment. www.PositiveIDCorp.com.

http://www.investorideas.com/news/2012/main/08062.asp